NCT03697551View on ClinicalTrials.gov

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 22, 2018

Primary Completion Date

February 6, 2019

Study Completion Date

February 6, 2019

Conditions

Breast Cancer

Interventions

DRUG

Satoreotide trizoxetan

Subjects will receive a single dose of Satoreotide trizoxetan consisting of a peptide mass up to 45 μg, with a radioactivity range of 150-200 MBq. Satoreotide trizoxetan is intended for diagnostic use as a Positron emission tomography/computed tomography (PET/CT) tracer for the imaging of tumours expressing SSTR2.

Trial Locations (1)

A-6020

Medical University Innsbruck, Innsbruck